van Geldorp Martijn W A, Eric Jamieson W R, Kappetein A Pieter, Ye Jian, Fradet Guy J, Eijkemans Marinus J C, Grunkemeier Gary L, Bogers Ad J J C, Takkenberg Johanna J M
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Thorac Cardiovasc Surg. 2009 Apr;137(4):881-6, 886e1-5. doi: 10.1016/j.jtcvs.2008.09.028. Epub 2009 Feb 25.
Although the results of aortic valve replacement with different valve prostheses are well documented in terms of survival, the risks of (valve-related) events are less well explored.
We used a dataset of 3934 patients who underwent aortic valve replacement with either a bioprosthesis (73%) or a mechanical prosthesis (27%) between 1982 and 2003 to simulate the outcome of patients after aortic valve replacement with either valve type. With the use of microsimulation, we compared total age and gender-specific life expectancy, event-free life expectancy, reoperation-free life expectancy, lifetime risks of reoperation, and valve-related events for both valve types.
The total follow-up was 26,467 patient-years. The mean follow-up was 6.1 years in the biological arm and 8.5 years in the mechanical arm. The mean age at implantation was 70 and 58 years for biological and mechanical prostheses, respectively, and the percentage of concomitant coronary artery bypass grafting was 47% and 28%, respectively. For a 60-year-old man, simulated life expectancy in years for biological versus mechanical prostheses was 11.9 versus 12.2, event-free life expectancy was 9.8 versus 9.3, and reoperation-free life expectancy was 10.5 versus 11.9. Lifetime risk of reoperation was 25% versus 3%. Lifetime risk of bleeding was 12% versus 41%.
Even for patients aged 60 years, event-free life expectancy is better with a bioprosthesis. Although the chance of reoperation is higher, the lifetime risk of bleeding is lower compared with a mechanical prosthesis. Comparing lifetime event risks between different types of valve prostheses provides more insight into patient outcome after aortic valve replacement and aids patient selection and counseling.
虽然不同瓣膜假体进行主动脉瓣置换术的生存结果已有充分记录,但(与瓣膜相关的)事件风险尚未得到充分研究。
我们使用了一个包含3934例患者的数据集,这些患者在1982年至2003年间接受了生物假体(73%)或机械假体(27%)的主动脉瓣置换术,以模拟这两种瓣膜类型的主动脉瓣置换术后患者的结局。通过微观模拟,我们比较了两种瓣膜类型的总年龄和性别特异性预期寿命、无事件预期寿命、无再次手术预期寿命、再次手术的终身风险以及与瓣膜相关的事件。
总随访时间为26467患者年。生物瓣膜组的平均随访时间为6.1年,机械瓣膜组为8.5年。生物瓣膜和机械瓣膜植入时的平均年龄分别为70岁和58岁,同期冠状动脉搭桥术的比例分别为47%和28%。对于一名60岁男性,生物瓣膜与机械瓣膜的模拟预期寿命(年)分别为11.9和12.2,无事件预期寿命为9.8和9.3,无再次手术预期寿命为10.5和11.9。再次手术的终身风险为25%对3%。出血的终身风险为12%对41%。
即使对于60岁的患者,生物瓣膜的无事件预期寿命也更好。虽然再次手术的几率更高,但与机械瓣膜相比,出血的终身风险更低。比较不同类型瓣膜假体之间的终身事件风险,能更深入了解主动脉瓣置换术后的患者结局,并有助于患者选择和咨询。